Wang et al. [40] demonstrated that glutamine transporter 2 (ASCT2) is highly expressed in prostate cancer tissues, and inhibiting the expression of ASCT2 in prostate cancer can reduce glutamine uptake, leading to downregulation of E2F cell cycle pathway proteins and mTORC1 pathway inhibition, thereby inhibiting the growth of prostate cancer cells. The gene discussed is SLC1A5; the disease is prostate carcinoma.